Full-Course ECMO Strategy for Moderate-to-Severe ARDS
Establishment and Evaluation of a Full-Course ECMO Management Strategy for Patients With Moderate-to-Severe ARDS
China faces major challenges in the ECMO management of patients with moderate-to-severe ARDS, including substantial heterogeneity in clinical practice, low weaning success rates, and high complication rates. A key underlying reason is the lack of a standardized full-course management pathway that is applicable to real-world clinical practice in China. This study focuses on the construction and evidence-based evaluation of a precision full-course ECMO management pathway for patients with moderate-to-severe ARDS, aiming to address fragmented care processes and delayed quality improvement.
The study includes three main components. First, multidisciplinary consensus and evidence-based findings will be integrated to develop a standardized management pathway covering the full chain of assessment, initiation, maintenance, weaning, and rehabilitation. Second, a nationwide multicenter real-world study with a before-and-after design will be conducted to systematically evaluate the clinical effectiveness of this pathway in reducing mortality and complications and improving patient outcomes. Third, a closed-loop dynamic optimization system based on "pathway-data-feedback-improvement" will be established. With the support of an intelligent data platform and multidisciplinary review mechanisms, the pathway will be continuously updated and refined.
Through this study, a reproducible, traceable, and evaluable full-course ECMO management strategy is expected to be established. The study will also build a national collaborative research network and support the development of living clinical guidance, promoting the transition of ECMO care in China from experience-based practice toward standardized, homogeneous, and intelligent management, and providing a key technical framework and practical model for improving critical care.
研究概览
详细说明
This study focuses on the establishment, clinical evaluation, and dynamic optimization of a full-course ECMO management pathway for patients with moderate-to-severe ARDS.
First, a standardized full-course ECMO management pathway will be developed based on evidence-based medicine and multidisciplinary collaboration. The pathway will cover the entire clinical process, including assessment of ECMO indications, ECMO initiation, maintenance management, complication prevention and management, ECMO weaning, rehabilitation, and follow-up. The aim is to standardize key clinical decision points and improve the homogeneity of ECMO care across participating centers.
Second, the clinical effectiveness of the full-course ECMO management pathway will be evaluated through a multicenter, real-world, before-and-after clinical study. Patients treated before implementation of the pathway will serve as the control group, while patients treated after implementation will receive care according to the standardized pathway. The study will systematically assess whether implementation of the pathway improves clinical outcomes in patients with moderate-to-severe ARDS receiving ECMO.
Third, a closed-loop system for pathway implementation and dynamic optimization will be established. This system will follow a "pathway-data-feedback-improvement" model. Based on updated guidelines and evidence generated from this study, key intervention points, process key performance indicators, and quality indicators will be defined. A unified electronic pathway and data dictionary will be used across participating centers. Physicians, respiratory therapists, and nurses will record key parameters and reasons for pathway deviations through an intelligent data platform.
Regular multidisciplinary reviews will be conducted monthly or quarterly to evaluate pathway implementation, identify process barriers, analyze center-level variation, and review the root causes of adverse events. Statistical process control, cumulative sum analysis, and risk-adjusted benchmarking may be used to support quality monitoring and continuous improvement. Based on the accumulated clinical data and evidence, living clinical guidance or practice recommendations will be updated iteratively.
The final goal of this study is to establish a reproducible, traceable, and evaluable full-course ECMO management pathway for patients with moderate-to-severe ARDS, thereby supporting standardized and homogeneous ECMO care across multiple centers.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:yingzi Huang, M.D.
- 电话号码:18271428804
- 邮箱:yz_huang@126.com
学习地点
-
-
-
Beijing、中国
- 招聘中
- Beijing AnZhen Hospital, Capital Medical University
-
接触:
- Zhongtao Du
-
Changchun、中国
- 尚未招聘
- The Second Hospital of Jilin University
-
Chengdu、中国
- 尚未招聘
- West China Tianfu Hospital, Sichuan University
-
Chenzhou、中国
- 尚未招聘
- The First People's Hospital of Chenzhou
-
Dalian、中国
- 招聘中
- The Second Affiliated Hospital of Dalian Medical University
-
Fuzhou、中国
- 招聘中
- Fuzhou University Affiliated Provincial Hospital
-
接触:
- Shang
-
Guangzhou、中国
- 招聘中
- The First Affiliated Hospital of Guangzhou Medical University
-
接触:
- Yan Wang
-
Hangzhou、中国
- 招聘中
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
接触:
- Xie
-
Hangzhou、中国
- 尚未招聘
- Affiliated Hangzhou First People's Hospital of Westlake University School of Medicine
-
Ha’erbin、中国
- 尚未招聘
- The First Affiliated Hospital of Harbin Medical University
-
Ha’erbin、中国
- 招聘中
- The Second Affiliated Hospital of Harbin Medical University
-
接触:
- Hongliang Wang
-
Huai'an、中国
- 尚未招聘
- Huai'an first people's hospital
-
Jinan、中国
- 招聘中
- Qilu Hospital of Shandong University
-
接触:
- Hao Wang
-
Kunshan、中国
- 尚未招聘
- The First People's Hospital of Kunshan
-
Lanzhou、中国
- 尚未招聘
- The First Hospital of Lanzhou University
-
Lianyungang、中国
- 尚未招聘
- The first people's hospital of Lianyungang
-
Liuzhou、中国
- 招聘中
- Liuzhou People's Hospital
-
接触:
- Wenfang Jiang
-
Nanjing、中国
- 尚未招聘
- Jiangsu Province Hospital
-
Nanjing、中国
- 招聘中
- Zhongda Hospital Southeast University
-
接触:
- Xiaojing Wu
- 电话号码:13951876234
- 邮箱:36410257@qq.com
-
Nanjing、中国
- 招聘中
- Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School)
-
接触:
- Danjiang Dong
-
Nanning、中国
- 尚未招聘
- The People's Hospital of Guangxi Zhuang Autonomous Region
-
Nanning、中国
- 尚未招聘
- The First Affiliated Hospital of Guangxi Medical University
-
Nanning、中国
- 尚未招聘
- The Second Affiliated Hospital of Guangxi Medical University
-
Nantong、中国
- 尚未招聘
- Affiliated Hospital of Nantong University
-
Ningxiang、中国
- 尚未招聘
- General Hospital of Ningxia Medical University
-
Qinghai、中国
- 尚未招聘
- The Affiliated Hospital of Qinghai University
-
Quzhou、中国
- 招聘中
- Quzhou people's Hospital
-
Sichuan、中国
- 招聘中
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (SAMS&SPPH, Affiliated Hospital of UESTC)
-
接触:
- Hongli He
-
Suining、中国
- 尚未招聘
- Suining Central Hospital
-
Suzhou、中国
- 尚未招聘
- The First Affiliated Hospital of Soochow University
-
Wuxi、中国
- 招聘中
- Wuxi People's Hospital
-
接触:
- Hongyang Xu
-
Xi'an、中国
- 招聘中
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
接触:
- jing Geng
-
Xiamen、中国
- 尚未招聘
- The First Affiliated Hospital of Xiamen University
-
Xinyang、中国
- 尚未招聘
- Xinyang Central Hospital
-
Xuzhou、中国
- 尚未招聘
- The Affiliated Hospital of Xuzhou Medical Universit
-
Yangzhou、中国
- 尚未招聘
- Northern Jiangsu People's Hospital
-
Zhengzhou、中国
- 招聘中
- Henan Provincial People's Hospital
-
接触:
- Huanzhang Shao
-
Zhengzhou、中国
- 尚未招聘
- The First Affiliated Hospital of Zhengzhou University
-
Zhongshan、中国
- 尚未招聘
- Zhongshan Hospital of Traditional Chinese Medicine
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- 1. Age 18 years or older. 2. Diagnosed with moderate-to-severe acute respiratory distress syndrome according to the global definition of ARDS.
Exclusion Criteria:
- 1. Patients with tracheostomy before screening. 2. Patients who have received lung transplantation or are receiving venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation.
3. Patients with cardiogenic shock requiring venoarterial ECMO or venoarterial-venous ECMO support.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Pre-Implementation Usual Care
Participants in this arm are patients with moderate-to-severe ARDS who received ECMO before implementation of the standardized full-course ECMO management pathway.
Clinical care will be provided according to usual practice at each participating center, including ECMO initiation, maintenance, complication management, weaning, and rehabilitation based on local protocols and clinician judgment.
|
Usual care refers to ECMO management provided before implementation of the standardized full-course ECMO management pathway.
Clinical decisions are made according to local practice and clinician judgment at each participating center.
|
|
实验性的:Post-Implementation ECMO Management Pathway
Participants in this arm are patients with moderate-to-severe ARDS who receive ECMO after implementation of the standardized full-course ECMO management pathway.
Clinical care will follow the pathway covering assessment of ECMO indications, ECMO initiation, maintenance management, complication prevention and management, weaning assessment, rehabilitation, and follow-up.
Individualized adjustments are allowed according to patient condition, and pathway deviations will be recorded.
|
The intervention is a standardized full-course ECMO management pathway for patients with moderate-to-severe ARDS.
The pathway covers assessment of ECMO indications, ECMO initiation, cannulation and anticoagulation strategies, mechanical ventilation management, hemodynamic and fluid management, infection prevention, analgesia and sedation, nutrition and rehabilitation, complication prevention and management, weaning assessment, discharge, and follow-up.
Individualized adjustments are allowed according to patient condition, and pathway deviations will be recorded for quality improvement and subsequent analysis.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
90-Day All-Cause Mortality
大体时间:From ECMO initiation to 90 days after ECMO initiation
|
From ECMO initiation to 90 days after ECMO initiation
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
28-Day All-Cause Mortality
大体时间:28 days after ECMO initiation
|
The proportion of participants who die from any cause within 28 days after ECMO initiation will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
28 days after ECMO initiation
|
|
Successful Liberation From Mechanical Ventilation
大体时间:From initiation of invasive mechanical ventilation to 7 days after liberation from mechanical ventilation, assessed up to hospital discharge
|
Successful liberation from mechanical ventilation is defined as survival without reintubation or death within 7 days after extubation in patients without tracheostomy, or survival without reconnection to mechanical ventilation or death within 7 days afte
|
From initiation of invasive mechanical ventilation to 7 days after liberation from mechanical ventilation, assessed up to hospital discharge
|
|
ICU Mortality
大体时间:From ICU admission to ICU discharge or death, assessed up to 90 days after ECMO initiation
|
The proportion of participants who die during the ICU stay will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
From ICU admission to ICU discharge or death, assessed up to 90 days after ECMO initiation
|
|
ICU Length of Stay
大体时间:From ICU admission to ICU discharge, assessed up to 90 days after ECMO initiation
|
ICU length of stay is defined as the number of days from ICU admission to ICU discharge or death.
|
From ICU admission to ICU discharge, assessed up to 90 days after ECMO initiation
|
|
Respiratory Support at ICU Discharge
大体时间:At ICU discharge, assessed up to 90 days after ECMO initiation
|
Respiratory support status at ICU discharge will be recorded, including tracheostomy, invasive mechanical ventilation, noninvasive ventilation or high-flow nasal cannula, conventional oxygen therapy, or no oxygen therapy.
|
At ICU discharge, assessed up to 90 days after ECMO initiation
|
|
Hospital Mortality
大体时间:From hospital admission to hospital discharge or death, assessed up to 90 days after ECMO initiation
|
The proportion of participants who die during hospitalization will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
From hospital admission to hospital discharge or death, assessed up to 90 days after ECMO initiation
|
|
Hospital Length of Stay
大体时间:From hospital admission to hospital discharge, assessed up to 90 days after ECMO initiation
|
Hospital length of stay is defined as the number of days from hospital admission to hospital discharge or death.
|
From hospital admission to hospital discharge, assessed up to 90 days after ECMO initiation
|
|
Respiratory Support at Hospital Discharge
大体时间:At hospital discharge, assessed up to 90 days after ECMO initiation
|
Respiratory support status at hospital discharge will be recorded, including tracheostomy, invasive mechanical ventilation, noninvasive ventilation or high-flow nasal cannula, conventional oxygen therapy, or no oxygen therapy.
|
At hospital discharge, assessed up to 90 days after ECMO initiation
|
|
Incidence of ECMO-Related Complications
大体时间:From ECMO initiation to 48 hours after ECMO decannulation
|
The incidence of ECMO-related complications will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
ECMO-related complications include major bleeding, minor bleeding, mechanical or circuit thrombosis, patient-related thrombosis, hospital-acquired infection during ECMO, hemolysis, cannulation-related complications, acute kidney injury, and oxygenator replacement.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Major Bleeding Events
大体时间:From ECMO initiation to 48 hours after ECMO decannulation
|
Major bleeding is defined as bleeding that meets at least one of the following criteria: life-threatening bleeding, including intracranial bleeding, retroperitoneal bleeding, cardiac tamponade, or bleeding leading to hemorrhagic shock; bleeding requiring surgical intervention; or transfusion of at least 2 units of red blood cells within 24 hours due to active bleeding.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Minor Bleeding Events
大体时间:From ECMO initiation to ECMO decannulation
|
Mechanical or circuit thrombosis is defined as thrombus formation observed or diagnosed within the extracorporeal circuit during ECMO support, including thrombosis in the ECMO oxygenator, pump head, tubing, connectors, or other circuit components.
|
From ECMO initiation to ECMO decannulation
|
|
Patient-Related Thrombotic Events
大体时间:From ECMO initiation to 48 hours after ECMO decannulation
|
Patient-related thrombotic events are defined as thrombotic or embolic events occurring within the patient's vascular system and confirmed by clinical findings, imaging, or autopsy.
Events include deep vein thrombosis, pulmonary embolism, and ischemic stroke.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Hospital-Acquired Infection During ECMO
大体时间:From 24 hours after ECMO initiation to 48 hours after ECMO decannulation
|
Hospital-acquired infection during ECMO is defined as infection occurring more than 24 hours after ECMO initiation and up to 48 hours after ECMO decannulation.
Infection sites include bloodstream infection, respiratory tract infection or ventilator-associated pneumonia, mediastinitis, cannulation-site or surgical-site infection, urinary tract infection, or other documented infection sites.
|
From 24 hours after ECMO initiation to 48 hours after ECMO decannulation
|
|
Hemolysis During ECMO
大体时间:From ECMO initiation to ECMO decannulation
|
Hemolysis is defined as plasma-free hemoglobin greater than 500 mg/L, equivalent to greater than 50 mg/dL, after ECMO cannulation.
|
From ECMO initiation to ECMO decannulation
|
|
Cannulation-Related Complications
大体时间:From ECMO cannulation to 48 hours after ECMO decannulation
|
Cannulation-related complications include limb ischemia, pseudoaneurysm, arteriovenous fistula, vascular dissection, or other vascular complications related to ECMO cannulation.
Limb ischemia is defined as impaired distal perfusion of the cannulated limb requiring clinical evaluation or intervention.
|
From ECMO cannulation to 48 hours after ECMO decannulation
|
|
Acute Kidney Injury During ECMO
大体时间:From ECMO initiation to ECMO decannulation
|
Acute kidney injury during ECMO will be assessed according to KDIGO criteria and classified as stage 1, stage 2, or stage 3.
The need for continuous renal replacement therapy will also be recorded.
|
From ECMO initiation to ECMO decannulation
|
|
Oxygenator Replacement
大体时间:From ECMO initiation to ECMO decannulation
|
Oxygenator replacement is defined as replacement of the ECMO oxygenator for any reason during ECMO support, including oxygenator thrombosis, gas exchange dysfunction, increased transmembrane pressure, hemolysis, or other clinical indications.
|
From ECMO initiation to ECMO decannulation
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2026ZDSYLL081-P01
- 2026ZD0555505 (其他赠款/资助编号:National Key R&D Program of China)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.